IMMUNIC INC. overview

Issuer: Immunic AG / Key word(s): Miscellaneous Immunic Highlights 2024 Accomplishments and Upcoming Milestones 07.01.2025 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Highlights 2024 Accomplishments and Upcoming Milestones – Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April – – Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of...

Issuer: Immunic AG / Key word(s): Conference Immunic, Inc. to Participate in Investor Conference in December 26.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Participate in Investor Conference in December NEW YORK, November 26, 2024 – Immunic , Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today...

Issuer: Immunic AG / Key word(s): Scientific publication Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology 13.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology – Includes Phase 1 Data in Healthy Human...

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Immunic, Inc. (NASDAQ:IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer, will present a company overview at the Q4 Investor Summit. The company will be available for 1-on-1 meetings throughout the day in addition to its presentation. Event: Q4 Investor Summit Presentation...

Issuer: Immunic AG / Key word(s): Quarter Results Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update 07.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update – Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and...

Issuer: Immunic AG / Key word(s): Miscellaneous Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update 31.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update – Webcast to be Held at 8:00 am ET on November 7, 2024 – NEW YORK, October 31, 2024 – Immunic, Inc....

Issuer: Immunic AG / Key word(s): Conference Immunic to Participate in Industry, Scientific and Investor Conferences in November 29.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Industry, Scientific and Investor Conferences in November NEW YORK, October 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic...

Issuer: Immunic AG / Key word(s): Study results Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis 22.10.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis – Based on a Review of Unblinded Data, an Independent Data Monitoring...